
Sign up to save your podcasts
Or
Blunt Business speaks with Dr. Benjamin Caplan, a distinguished family medicine doctor and member of the American Medical Association, who has overseen the healthcare journey of over 250,000 patients exploring the benefits of medical cannabis. Dr. Caplan recently published "The Doctor-Approved Cannabis Handbook," delving into the safe use of cannabis for managing various conditions like cognitive decline, cancer, chronic pain, depression, diabetes, insomnia, and headaches. Discover the effort behind building this comprehensive guide and gain valuable insights into incorporating cannabis treatment into everyday health.
Learn about the recent scientific review recommending the reclassification of marijuana from Schedule I to Schedule III, potentially opening new medical possibilities. Dr. Caplan shares his perspective on the implications this could have, including the potential end of IRS Section 280e restrictions.
Addressing federal scientists catching up with medical knowledge, Dr. Caplan reflects on whether the recent conclusions align with what doctors have known for years. Finally, hear Dr. Caplan's response to criticisms highlighted by The New York Times, addressing concerns about the strength and frequency of marijuana use, its ties to psychiatric problems, and the evolving landscape of therapeutic claims.
4.1
3939 ratings
Blunt Business speaks with Dr. Benjamin Caplan, a distinguished family medicine doctor and member of the American Medical Association, who has overseen the healthcare journey of over 250,000 patients exploring the benefits of medical cannabis. Dr. Caplan recently published "The Doctor-Approved Cannabis Handbook," delving into the safe use of cannabis for managing various conditions like cognitive decline, cancer, chronic pain, depression, diabetes, insomnia, and headaches. Discover the effort behind building this comprehensive guide and gain valuable insights into incorporating cannabis treatment into everyday health.
Learn about the recent scientific review recommending the reclassification of marijuana from Schedule I to Schedule III, potentially opening new medical possibilities. Dr. Caplan shares his perspective on the implications this could have, including the potential end of IRS Section 280e restrictions.
Addressing federal scientists catching up with medical knowledge, Dr. Caplan reflects on whether the recent conclusions align with what doctors have known for years. Finally, hear Dr. Caplan's response to criticisms highlighted by The New York Times, addressing concerns about the strength and frequency of marijuana use, its ties to psychiatric problems, and the evolving landscape of therapeutic claims.
596 Listeners
32,531 Listeners
30,050 Listeners
10 Listeners
569 Listeners
9 Listeners
20 Listeners
121 Listeners
3 Listeners
14 Listeners
3 Listeners
5 Listeners
112 Listeners
51 Listeners
2 Listeners
12 Listeners
57,900 Listeners
128 Listeners
104 Listeners
325 Listeners
214 Listeners
7 Listeners
7 Listeners
13 Listeners